Year: 2013
Type: editorial
Abstract: Therapeutic monoclonal antibodies (mAbs) are a proven therapeutic platform, but they cannot readily cross the cell membranes to bind intracellular antigens, while some of the most important disease-associated proteins are intracellular, protected from direct mAb attack. However, the cellular processes of necrosis and major histocompatibility complex (MHC) class I antigen presentation expose epitopes from intracellular proteins to the extracellular environment or cell surface. Antibodies that exploit these processes can therefore specifically target diseased cells based on their intracellular protein content. These strategies expose important new targets for mAb therapy and expand the potential for effective therapies.
Authors: Nicholas Veomett, Tao Dao, David A Scheinberg
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Cancer Institute
Award: Cancer Pharmacology
OpenAlex ID: W2171963514